ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02576496
Previous Study | Return to List | Next Study

Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02576496
Recruitment Status : Recruiting
First Posted : October 15, 2015
Last Update Posted : April 18, 2018
Sponsor:
Information provided by (Responsible Party):
Mundipharma-EDO GmbH

Brief Summary:
This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed/refractory hematologic malignancies. All patients will receive EDO-S101.

Condition or disease Intervention/treatment Phase
Hematological Malignancies Multiple Myeloma Hodgkin's Lymphoma Peripheral T-cell Lymphoma Non-Hodgkin's Lymphoma Drug: EDO-S101 Phase 1

Detailed Description:

EDO-S101 is a new chemical entity, a first-in-class fusion molecule of an alkylator, bendamustine and a histone-deacetylase inhibitor (HDACi), vorinostat. It is anticipated that EDO-S101 may have activity in various hematological malignancies and solid tumors. This phase 1 study will enroll patients with various hematological malignancies.

The study consists of 2 stages:

  • Stage 1: Dose Escalation to determine Maximum Tolerated Dose (MTD) at the optimal infusion time and the pharmacokinetic (PK) profiles; is expected to enroll between 21 and 48 patients
  • Stage 2: Expansion in four Cohorts, in which approximately 12 patients will be enrolled per cohort, for a total of 48 patients.

In Stage 1, EDO-S101 doses will be escalated following the standard 3+3 design. The decision to escalate to the next dose level will occur after all cohort patients have completed 3 weeks (21 days) of observation and have been evaluated for safety and toxicity.The starting dose is a 1 hour infusion of 20 mg/m2, and the maximum dose level is 150 mg/m2. Reduced infusion times of 45 minutes and 30 minutes will also be assessed once the maximum tolerated dose at a 1-hour infusion is determined.

In Stage 2, four cohorts of patients (with relapsed/refractory multiple myeloma or Waldenström Macroglobulinemia; relapsed/refractory Hodgkin's lymphoma; relapsed/refractory peripheral T-cell lymphoma, or relapsed/refractory non-Hodgkin's lymphoma [except chronic lymphocytic and cutaneous T-cell lymphoma] who have been treated or are refractory to bendamustine); and relapsed/refractory peripheral T-cell lymphoma (PTCL) and T-cell Prolymphocytic leukemia (T-PLL) will be enrolled and treated at the recommended Phase 2 dose (RP2D) based on results of Stage 1. Treatment will occur every 21 days. Patients in each stage of the study are expected to receive a median of four 3-week Cycles of therapy, and the maximum number of treatment Cycles allowed is 6.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Study Start Date : March 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : May 2019


Arm Intervention/treatment
Experimental: EDO-S101
EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle
Drug: EDO-S101



Primary Outcome Measures :
  1. Maximum Tolerated Dose at optimal infusion time [ Time Frame: 8 months ]
    maximum tolerated dose at optimal infusion time

  2. Maximum plasma concentration (Cmax) of EDO-S101 [ Time Frame: 8 months ]
    maximum plasma concentration of EDO-S101 in stage 1

  3. Confirm recommended phase 2 dose (RP2D) [ Time Frame: 10 months from beginning of stage 2 ]
    In stage 2, confirm recommended phase 2 dose.

  4. Overall response rate [ Time Frame: 10 months from beginning stage 2 ]
    Determine overall response rate

  5. EDO-S101 Area under the curve (AUC) [ Time Frame: 8 months ]
    Determine EDO-S101 AUC in plasma


Secondary Outcome Measures :
  1. Progression free survival time [ Time Frame: 10 months after beginning stage 2 ]
    Determine the progression free survival time for patients who received the RP2D

  2. Overall survival [ Time Frame: 10 months after beginning stage 2 ]
    Determine overall survival time for patients who received the RP2D

  3. Maximum plasma concentration of EDO-S101 in patients receiving RP2D [ Time Frame: 10 months after beginning stage 2 ]
    Determine maximum plasma concentration of EDO-S101 in patients receiving the RP2D in stage 2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Execute an informed consent.
  2. Patients age ≥18 years at signing the informed consent.
  3. Diagnosis of relapsed or refractory lymphoid malignancy for which there are no available therapies.
  4. Discontinuation of previous cancer therapies at least four (4) weeks prior to treatment in this study.
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  6. Neutrophils >1,000 µL
  7. Platelets ≥75,000 µL
  8. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 upper limit of normal (ULN).
  9. Total bilirubin <2.0 mg/dL unless elevated due to known Gilbert's syndrome.
  10. Creatinine ≤1.5 ULN.
  11. Serum potassium within normal range.
  12. If female of child-bearing potential (i.e. not postmenopausal or surgically sterile), must be willing to abstain from sexual intercourse or employ an effective barrier or medical method of contraception during the study drug administration and follow-up periods. If male, must be sterile or willing to abstain from sexual intercourse or employ a barrier method of contraception during the study treatment and follow-up periods.

Exclusion Criteria:

  1. Patients with any central nervous system involvement or CTCL.
  2. Diagnosis of acute leukemia or any patient that has been treated with fludarabine.
  3. Allogeneic stem cell transplant patients and any patient who has relapsed within 100 days of stem cell infusion following an autologous bone marrow transplant.
  4. Patients with QTc interval > 450 msec.
  5. Patients who are on treatment with drugs known to prolong the QT/QTc interval.
  6. Any serious medical condition that interferes with adherence to study procedures.
  7. Patients with a history of a second malignancy diagnosed within three (3) years of study enrollment excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  8. Pregnant or breast feeding females.
  9. New York Heart Association (NYHA) stage III/IV congestive heart failure, arrhythmias not adequately controlled, active infections, or other significant co-morbidities [e.g. active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.
  10. Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed four (4) weeks prior to first dose of study drug or without complete recovery from all such treatments.
  11. Use of other investigational agents from 30 days prior to the Screening Visit through discontinuation of study drug.
  12. Steroid treatment within seven (7) days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to 10 mg PO QD or less seven (7) days prior to study drug administration are allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02576496


Locations
United States, Arizona
Mayo Clinic Recruiting
Phoenix, Arizona, United States, 85054
Contact: Leif Bergsagel, MD    480-301-8335    bergsagel.leif@mayo.edu   
Principal Investigator: Leif Bergsagel, MD         
United States, Florida
Mayo Clinic Cancer Center Recruiting
Jacksonville, Florida, United States, 32224
Contact: Han W Tun, MD    904-953-7290    tun.han@mayo.edu   
Contact: Kathleen M Burke, RN    904 953 6174    burke.kathleen@mayo.edu   
Principal Investigator: Han W. Tun, MD         
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10019
Contact: Owen A O'Connor, MD,PhD    212-326-5720    oo2130@cumc.columbia.edu   
Contact: Michelle A Malanga, MPA    212-326-5731    mm4629@cumc.columbia.edu   
Germany
University Hospital of Heidelberg - medical department V Not yet recruiting
Heidelberg, Germany, 69120
Principal Investigator: Hartmut Goldschmidt, MD         
University Hospital of Cologne - Department I of Internal Medicine Not yet recruiting
Köln, Germany, 50937
Principal Investigator: Von Treskow, MD         
Italy
Institute of Hematology "L. A. Seràgnoli", University of Bologna Recruiting
Bologna, Italy, 40138
Contact: Luigi Zinzani, MD    +39 0512143680    pierluigi.zinzani@unibo.it   
Principal Investigator: Luigi Zinzani, MD         
National Cancer Institute, Fondazione 'G. Pascale' Recruiting
Naples, Italy, I-80131
Contact: Antonio Pinto, MD    +39 081 5903 382    apinto.int.napoli@tin.it   
Principal Investigator: Antonio Pinto, MD         
Switzerland
Kantonsspital St.Gallen Recruiting
St.Gallen, Switzerland, 9007
Contact: Christoph Driessen, MD    41 71 494 11 62    christoph.driessen@kssg.ch   
Principal Investigator: Christoph Driessen, MD         
Sponsors and Collaborators
Mundipharma-EDO GmbH
Investigators
Principal Investigator: Owen A O'Connor, MD,PhD Columbia University

Responsible Party: Mundipharma-EDO GmbH
ClinicalTrials.gov Identifier: NCT02576496     History of Changes
Other Study ID Numbers: EDO-S101-1001
First Posted: October 15, 2015    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: relevant patient listing data of de-identified patients may be reviewed

Keywords provided by Mundipharma-EDO GmbH:
phase 1 clinical trial
multiple myeloma
Hodgkin's lymphoma
peripheral T-cell lymphoma
non-Hodgkin's lymphoma

Additional relevant MeSH terms:
Lymphoma
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms
Lymphoma, Non-Hodgkin
Hodgkin Disease
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders